Accession Number : ADA581049


Title :   Vesicant Therapeutics Collaborative Core Research Program


Descriptive Note : Final rept. 1 Jun 2010-30 Nov 2012


Corporate Author : JOHNS HOPKINS UNIV BALTIMORE MD


Personal Author(s) : Mao, Hai-Quan


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a581049.pdf


Report Date : Dec 2012


Pagination or Media Count : 31


Abstract : This project at Johns Hopkins University serves as the In Vivo Delivery System Development Core of the Phase I Vesicant Therapeutics Collaborative Core Research Program (VT-CCRP). The Mission of this Core is focused on achieving Aim 3 of the Parent Grant at the USAMRICD. This Core aims to develop, evaluate, and downselect a nanotechnology-based system for in vivo RNAi delivery. This will be a critical component of validating therapeutic targets identified by the Target Discovery and In Vitro Validation Core in in vivo models of vesicant exposure. The Specific Aims are to evaluate nanotechnology-based delivery systems for RNAi delivery, to confirm delivery to target tissues in vivo, confirm knockdown of target in vivo, and to select the most effective delivery system for validation of targets in vivo. Two delivery systems, chitosan nanoparticles and PEG-PPA nanoparticles, will be under development and evaluation.


Descriptors :   *DEOXYRIBONUCLEIC ACIDS , *RIBONUCLEIC ACIDS , *VESICANTS , THERAPY , TISSUES(BIOLOGY)


Subject Categories : Genetic Engineering and Molecular Biology
      Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE